Clinical Trial Update: A Safety and Efficacy Study of Xolair in Peanut Allergy [Phase 2]

View source ↗

Summary

Phase 2 safety and efficacy trial of Xolair (omalizumab) for peanut allergy has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peanut Allergy

Drugs mentioned

• Xolair (omalizumab)

Snippet

Sponsor: Genentech, Inc. | Conditions: Allergy | Phase 2 | Status: TERMINATED